WikiJournal of Medicine/Volume 5 Issue 1: Difference between revisions
No edit summary |
No edit summary |
||
Line 6: | Line 6: | ||
{{Issue header|year = 2018 |volume = 5 |issue = 1 |current = true}} |
{{Issue header|year = 2018 |volume = 5 |issue = 1 |current = true}} |
||
{{List entry |
{{List entry |
||
|title = Western African Ebola virus epidemic |
|||
|journal = WikiJournal of Medicine |
|journal = WikiJournal of Medicine |
||
|last1 = Anis |
|last1 = Anis |
Revision as of 11:29, 11 May 2019
WikiJournal of Medicine
Open access • Publication charge free • Public peer review • Wikipedia-integrated
VOLUME 5 (2018)
ISSUE 1
Current issue
Authors: {{{authors_plain}}}
The Western African Ebola virus epidemic (2013–2016) was the most widespread outbreak of Ebola virus disease (EVD) in history—causing major loss of life and socioeconomic disruption in the region, mainly in the countries of Guinea, Liberia, and Sierra Leone. The first cases were recorded in Guinea in December 2013; later, the disease spread to neighboring Liberia and Sierra Leone, with minor outbreaks occurring elsewhere. It caused significant mortality, with the case fatality rate reported which was initially considerable, while the rate among hospitalized patients was 57–59%, the final numbers 28,616 people, including 11,310 deaths, for a case-fatality rate of 40%. * Small outbreaks occurred in Nigeria and Mali, * and isolated cases were recorded in Senegal, the United Kingdom and Italy. In addition, imported cases led to secondary infection of medical workers in the United States and Spain but did not spread further. * The number of cases peaked in October 2014 and then began to decline gradually, following the commitment of substantial international resources. As of 8 May 2016[update]World Health Organization (WHO) and respective governments reported a total of 28,616 suspected cases and 11,310 deaths (39.5%), though the WHO believes that this substantially understates the magnitude of the outbreak. * doi: 10.15347/wjm/2019.002 [[{{{journal}}}/Anthracyclines|Anthracyclines]]
Authors: {{{authors_plain}}}
Anthracyclines are a clinically important class of antineoplastic agents used to treat a wide variety of solid and blood cancers. The first described anthracycline, daunorubicin, was first isolated from a strain of Streptomyces peucetius in the early 1960s. Clinically the most widely used are doxorubicin, daunorubicin and their semi-synthetic derivatives epirubicin and idarubicin. They primarily act by intercalating with DNA and inhibiting topoisomerase II, resulting in DNA breaks and abrogated DNA synthesis. The most serious side effect of anthracycline use is cumulative dose-dependent cardiotoxicity, limiting recommended maximum lifetime treatment to 400-450 mg/m2. Several liposomal formulations of doxorubicin are in use, having the benefits of prolonging retention rate while reducing peak plasma concentration of free drug. Several clinical trials of anthracycline-loaded nanoparticles are currently underway. doi: 10.15347/wjm/2018.001
|
WikiJournal of Medicine
www.WikiJMed.org On social media RSS feed
[
]2020:
2019:
2018:
|
Cite error: <ref>
tags exist for a group named "note", but no corresponding <references group="note"/>
tag was found